While 503B facilities are required to follow current Good Manufacturing Practices (cGMP), the compounded drugs themselves are not FDA-approved. If semaglutide and tirzepatide are removed from the 503B bulks list, the availability of compounded GLP-1s would drop significantly, Michael Snyder, MD, FACS, FASMBS, DABOM, medical director of the Bariatric Surgery Center at Rose Medical Center, founder and director of the Denver Center for Bariatric Surgery Foundation, and in-house obesity specialist at FuturHealth, told MNT
Can Lactose Intolerance Be a Cause of Constipation
The new proceeding, MDL No
The market is shifting, and leading competitors are already bundling perks like discount meal plans or mental health support
Ehlers M, Jordan AL, Feldkamp J, Fritzen R, Quadbeck B, Haase M, Allelein S, Schmid C, Schott M